CTBO (Cantabio Pharmaceuticals) Ending Cash Position: $0.28 Mil (As of Dec. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals Ending Cash Position?

Cantabio Pharmaceuticals CTBO Ending Cash Position is $0.28 Mil as of Dec. 2018.

Cantabio Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2018 was $0.28 Mil.

Cantabio Pharmaceuticals's quarterly Ending Cash Position declined from Jun. 2018 ($0.19 Mil) to Sep. 2018 ($0.02 Mil) but then increased from Sep. 2018 ($0.02 Mil) to Dec. 2018 ($0.28 Mil).

Cantabio Pharmaceuticals's annual Ending Cash Position declined from Mar. 2016 ($0.05 Mil) to Mar. 2017 ($0.03 Mil) but then increased from Mar. 2017 ($0.03 Mil) to Mar. 2018 ($0.11 Mil).

Cantabio Pharmaceuticals Ending Cash Position Related Terms

Cantabio Pharmaceuticals Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Ending Cash Position Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Ending Cash Position
Get a 7-Day Free Trial 0.01 0.00 0.05 0.03 0.11

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.11 0.19 0.02 0.28

Cantabio Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cantabio Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Mar. 2018 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.031+0.078
=0.11

Cantabio Pharmaceuticals's Ending Cash Position for the quarter that ended in Dec. 2018 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.021+0.262
=0.28

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.28 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Ending Cash Position of $0.28 Mil as of Dec. 2018. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Ending Cash Position too high?
Cantabio Pharmaceuticals' current Ending Cash Position is $0.28 Mil.
How does Cantabio Pharmaceuticals' Ending Cash Position compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Ending Cash Position of $0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Ending Cash Position is $0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Ending Cash Position of $0.28 Mil. The current Ending Cash Position is $0.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Ending Cash Position is $0.28 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.